15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Foghorn Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $13.00, so the covering firms are broadly aligned. The average target of $11.67 sits 142% above the current $4.82. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.22 next quarter toward $-1.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Foghorn Therapeutics Inc.
As of Sep, 6 of 6 firms rate FHTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FHTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.33 – $-0.15 · 7 analysts · -40% YoY
Next period, 7 analysts expect Foghorn Therapeutics Inc to earn $-0.22 a share (range $-0.33 – $-0.15), versus $-0.37 a year earlier. Full-year consensus is $-0.88, growing to $-1.09 the year after.
REVENUE · NEXT QUARTER
$8.3M
Range $3.6M – $12.5M · 7 analysts · -10% YoY
Revenue is expected to reach $8.3M (range $3.6M – $12.5M), -9.8% year-over-year. Full-year consensus is $33.9M, rising to $32.8M next year.
Top analysts covering Foghorn Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FHTX.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$12.00+149.0% to target
Overall win rate
55%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #26
Buy
$9.00+86.7% to target
Overall win rate
53%
+ Follow
#3
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$13.00+169.7% to target
Overall win rate
46%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #227
Buy
$13.00+169.7% to target
Overall win rate
39%
+ Follow
#5
Robert Driscoll
Wedbush · Rank #375
Buy
$10.00+107.5% to target
Overall win rate
30%
+ Follow
FHTX stock forecast FAQ
What is FHTX's average 12-month price target?+
The 6 analysts with a live target average $11.67 for Foghorn Therapeutics Inc over the next 12 months, ranging from a $13.00 high to a $10.00 low.
Is FHTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FHTX?+
The Street-high target is $13.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Wedbush). The average of all 6 active targets is $11.67.
How many Wall Street analysts cover FHTX?+
6 analysts have an active rating on Foghorn Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering FHTX?+
Among analysts who currently cover FHTX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $12.00 target.
What is Foghorn Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.33 – $-0.15) across 7 analysts. Full-year EPS is projected at $-0.88, rising to $-1.09 the following year.
How much revenue is Foghorn Therapeutics Inc expected to report next quarter?+
Consensus revenue is $8.3M (range $3.6M – $12.5M). Full-year revenue is projected at $33.9M, growing to $32.8M next year.
Have analysts been upgrading or downgrading FHTX lately?+
As of Sep, 6 of 6 firms rate FHTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FHTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
